Survey Results: What Sponsors Say Is Slowing Cancer Trials — and What’s Helping

Why It Matters

Extended timelines inflate costs and delay life‑saving therapies, threatening competitive advantage and patient outcomes. Addressing the identified bottlenecks can streamline drug development and improve market access for oncology treatments.

Key Takeaways

• Protocol amendments extend timelines by months
• Site coordination struggles increase operational costs
• Patient recruitment delays remain primary enrollment hurdle
• Digital platforms streamline data capture and monitoring
• Adaptive designs reduce amendment frequency and study duration

Pulse Analysis

The oncology trial landscape is evolving toward greater molecular complexity, which translates into longer protocols and more frequent mid‑study changes. Sponsors cited universal post‑launch amendments, a symptom of evolving scientific hypotheses and regulatory feedback. These amendments not only push back milestones but also strain site staff, inflate budgets, and delay data lock, creating a ripple effect that can jeopardize funding cycles and partnership timelines.

Beyond protocol volatility, the survey underscored chronic challenges in patient recruitment and site execution. Oncology studies often target narrow biomarker‑defined populations, making enrollment a rate‑limiting step. Simultaneously, sites grapple with fragmented data capture systems and limited staffing, leading to inconsistent monitoring and quality issues. The convergence of these factors amplifies trial duration and erodes return on investment, prompting sponsors to seek more resilient operational models.

To counteract these pressures, respondents highlighted technology‑driven solutions and flexible trial designs. Centralized electronic data capture platforms, real‑time analytics, and remote monitoring reduce manual workload and accelerate decision‑making. Adaptive trial designs allow predefined protocol modifications without full amendments, preserving timelines while maintaining scientific rigor. By integrating these approaches, sponsors can mitigate friction, lower costs, and bring innovative cancer therapies to patients faster.